| 1 |
Germani G,Rodriguez-Castro K,Russo FP, et al. Markers of acute rejection and graft acceptance in liver transplantation[J]. World J Gastroenterol, 2015，21(4): 1061-1068.
|
| 2 |
Kotsch K,Ulrich F,Reutzel-Selke A, et al. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial[J]. Ann Surg, 2008，248(6): 1042-1050.
|
| 3 |
Benítez CE,Puig-Pey I,López M, et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation[J]. Am J Transplant, 2010，10(10): 2296-2304.
|
| 4 |
Flechner SM,Kobashigawa J,Klintmalm G. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity[J]. Clin Transplant, 2008，22(1): 1-15.
|
| 5 |
Sgourakis G,Dedemadi G. Corticosteroid-free immunosuppression in liver transplantation: an evidence-based review[J]. World J Gastroenterol, 2014，20(31): 10703-10714.
|
| 6 |
Magliocca JF,Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation[J]. Transpl Int, 2006，19(9): 705-714.
|
| 7 |
Turner AP,Knechtle SJ. Induction immunosuppression in liver transplantation: a review[J]. Transpl Int, 2013，26(7): 673-683.
|
| 8 |
Boillot O,Seket B,Dumortier J, et al. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study[J]. Liver Transpl, 2009，15(11): 1426-1434.
|
| 9 |
耿兴超,周洋,林志，等. 抗CD3单克隆抗体对食蟹猴免疫功能及相关基因表达的影响[J]. 中国药学杂志，2016，51(1): 20-27.
|
| 10 |
Kauffman HM,Cherikh WS,McBride MA, et al. Deceased donors with a past history of malignancy: an organ procurement and transplantation network/united network for organ sharing update[J]. Transplantation, 2007，84(2): 272-274.
|
| 11 |
尤平洪,卢一平. 一种新型的IL-2R受体阻滞剂——抗CD25单克隆抗体[J]. 华西医学，2007，22(3): 659-660.
|
| 12 |
Hanaway MJ,Woodle ES,Mulgaonkar S, et al. Alemtuzumab induction in renal transplantation[J]. N Engl J Med, 2011，364(20): 1909-1919.
|
| 13 |
Macklin PS,Morris PJ,Knight SR. A systematic review of the use of rituximab as induction therapy in renal transplantation[J]. Transplant Rev (Orlando), 2015，29(2): 103-108.
|
| 14 |
van den Hoogen MW,Kamburova EG,Baas MC, et al. Rituximab as induction therapy after renal transplantation: a randomized, double-blind, placebo-controlled study of efficacy and safety[J]. Am J Transplant, 2015，15(2): 407-416.
|
| 15 |
Galante NZ. Induction treatment in renal transplantation[J]. J Bras Nefrol, 2015，37(2): 156-157.
|
| 16 |
Wiseman AC. Induction therapy in renal transplantation: Why? What Agent? What Dose? We may never know[J]. Clin J Am Soc Nephrol, 2015，10(6): 923-925.
|
| 17 |
倪之嘉,丁国善,于勇，等. 巴利昔单抗在预防肝移植术后排斥反应中的应用[J]. 第二军医大学学报，2007，28(6): 678-680.
|
| 18 |
刘颖,朱志军. 达利珠单抗免疫诱导治疗在肝移植后的应用[J]. 中国组织工程研究，2013，17(31): 5601-5606.
|
| 19 |
Xiao M,Xu X,Zhu H, et al. Efficacy and safety of basiliximab in liver transplantation for patients with hepatitis B virus-related diseases: a single centre study[J]. Int J Clin Pract Suppl, 2015，69(183): 35-42.
|
| 20 |
Onali S,Mansell A,Aspite S, et al. Reduced calcineurin inhibitor exposure early after liver transplantation protects against renal dysfunction independently of the use of basiliximab induction therapy[J]. J Hepatol, 2015，62 (S2): S323-S324.
|
| 21 |
Hagopian J,Horwedel T,Bowman L, et al. Renal function following basiliximab induction in liver transplant recipients[J]. Am J Transplant, 2015，15 (S3)．
|
| 22 |
Werth J,Ally W,Maluf D, et al. Basiliximab induction with delayed tacrolimus initiation up to 14 days post liver transplantation maintains excellent clinical outcomes while preserving renal function[J]. Am J Transplant, 2015，15 (S3)．
|
| 23 |
Hibi T,Shinoda M,Itano O, et al. Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus-related cirrhosis[J]. Hepatol Res, 2015，45(12): 1178-1184.
|
| 24 |
Goralczyk AD,Hauke N,Bari N, et al. Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies[J]. Hepatology, 2011，54(2): 541-554.
|
| 25 |
Crins ND,Röver C,Goralczyk AD, et al. Interleukin-2 receptor antagonists for pediatric liver transplant recipients: a systematic review and meta-analysis of controlled studies [J]. Pediatr Transplant, 2014，18(8): 839-850.
|
| 26 |
Wang XF,Li JD,Peng Y, et al. Interleukin-2 receptor antagonists in liver transplantation: a meta-analysis of randomized trials[J]. Transplant Proc, 2010，42(10): 4567-4572.
|
| 27 |
Hall D,Puri S,Mabry S, et al. Forty-seven consecutive simultaneous liver-kidney transplants with steroid free immunosuppression after rabbit antithymocyte globulin induction[J]. Am J Transplant, 2015，15 (S3)．
|
| 28 |
Yoo MC,Vanatta JM,Modanlou KA, et al. Steroid-free liver transplantation using rabbit antithymocyte globulin induction in 500 consecutive patients[J]. Transplantation, 2015，99(6): 1231-1235.
|
| 29 |
Penninga L,Wettergren A,Wilson CH, et al. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients[J]. Cochrane Database Syst Rev, 2014，(6): CD010253.
|
| 30 |
Penninga L,Wettergren A,Wilson CH, et al. Antibody induction versus corticosteroid induction for liver transplant recipients[J]. Cochrane Database Syst Rev, 2014，(5): CD010252.
|
| 31 |
Montenovo MI,Jalikis FG,Li M, et al. Superior patient and graft survival in adult liver transplantation with rabbit antithymocyte globulin induction: Experience with 595 patients[J]. Exp Clin Transplant, 2017，15(4): 425-431.
|
| 32 |
Uemura T,Schaefer E,Hollenbeak CS, et al. Outcome of induction immunosuppression for liver transplantation comparing anti-thymocyte globulin, daclizumab, and corticosteroid[J]. Transpl Int, 2011，24(7): 640-650.
|
| 33 |
Lu B,Park KT,Balise RR, et al. The use of daclizumab or antithymocyte globulin (ATG) for induction in pediatric liver transplantation does not increase the risk of epstein-barr virus (EBV) viremia post transplantation but does shorten the time interval to the development[J]. Hepatology, 2011，54 (S1): 706A-707A.
|
| 34 |
Hotta R,Ohira M,Matsuura T, et al. CD52-negative NK cells are abundant in the liver and less susceptible to alemtuzumab treatment[J]. PloS One, 2016，11 (8): e0161618.
|
| 35 |
Uryuhara K. Successful protocol with rituximab in adult living donor liver transplantation across ABO barrier[J]. Transpl Int, 2015，28 (S4): 201.
|
| 36 |
Lee J,Lee JG,Song SH, et al. Results of ABO incompatible liver transplantation using a simplified protocol at a single institution[J]. Transpl Int, 2015，28 (S4): 5.
|
| 37 |
Song GW,Lee SG,Hwang S, et al. ABO-incompatible adult living donor liver transplantation under the desensitization protocol with rituximab[J]. Am J Transplant, 2016，16(1): 157-170.
|
| 38 |
Egawa H,Umeshita K,Uemoto S. The best regimen with rituximab for ABO-incompatible living donor liver transplantation[J]. Am J Transplant, 2015，15 (S3)．
|
| 39 |
Lee S,Kim SH,Park SJ, et al. ABO incompatible living donor liver transplantation using rituximab without plasma exchange[J]. HPB (Oxford), 2015，17 (S2): 59.
|
| 40 |
Okada N,Snada Y,Hirata Y, et al. The impact of rituximab in ABO-incompatible pediatric living donor liver transplantation: the experience of a single center[J]. Pediatr Transplant, 2015，19(3): 279-286.
|